ArticleThe Journal of experimental medicine2025
Intravenous BCG-mediated protection against tuberculosis requires CD4+ T cells and CD8α+ lymphocytes.
Article in The Journal of experimental medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed.
- Route of BCG administration determines success.Human vaccines & immunotherapeutics · 2026Review
- Population-level genome sequencing reveals distinctmSystems · 2026Article
- IFN𝛾 and IFN𝛾 mimetics prevent IFN-I-mediated TB susceptibility by regulating iron metabolism and lipid peroxidation.bioRxiv : the preprint server for biology · 2026Article
- The host immune response to Mycobacterium tuberculosis determining protection or disease progression.Nature immunology · 2026Review
- HowVaccines · 2026Review
- Review
- Role of Donor Unrestricted T Cells (DURTs) in TB Host Defense: Implications for Novel TB Vaccine Development.Vaccines · 2026Review
- Immunodominant Tuberculosis Antigens Recognized by Human CD4Cold Spring Harbor perspectives in medicine · 2026Article
- Immunological mechanistic action of intravenous BCG-mediated protection against tuberculosis.Cellular and molecular life sciences : CMLS · 2026Review
- Single-cell profiling reveals that dynamic lung immune responses distinguish protection from susceptibility to tuberculosis.PLoS pathogens · 2026Article
- BCG vaccination reduces the rate of Mycobacterium tuberculosis dissemination between murine lungs.Research square · 2026Article
- CD8Nature communications · 2026Article
- BCG vaccination reduces the rate of Mycobacterium tuberculosis dissemination between murine lungs.bioRxiv : the preprint server for biology · 2026Article
- Predictive role of systemic immune-inflammation index (SII) in tuberculosis infection morbidity and ICU tuberculosis patient mortality: an observational study.Journal of thoracic disease · 2026Article
- Protection against reinfection with Mycobacterium tuberculosis extends across heterologous Mtb lineages.Mucosal immunology · 2026Article
- IFN-γ- GranzymeB + Natural killer cells are induced by IV BCG vaccination and associated with protection against tuberculosis in rhesus macaques.Mucosal immunology · 2026Article
- Evolution of the tuberculin skin test reveals generalisable Mtb-reactive T cell metaclones.Nature communications · 2026Article
- BCG vaccination induces antibacterial effector functions among Vδ1/3 T cells that are associated with protection against tuberculosis.Cell reports. Medicine · 2026Article
- Clinical and hematological factors associated with neurological involvement in spinal tuberculosis: a retrospective study.Frontiers in cellular and infection microbiology · 2026Article
- Using Imaris to rigorously track PET-defined sites of lung inflammation inAmerican journal of diagnostic imaging · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
32 authors.
Funding
Abstract
Tuberculosis (TB) is a major health burden worldwide despite widespread intradermal (ID) BCG vaccination in newborns. We previously demonstrated that changing the BCG route and dose from 5 × 105 CFUs ID to 5 × 107 CFUs i.v. resulted in prevention of Mycobacterium tuberculosis (Mtb) infection and TB disease in highly susceptible nonhuman primates. Identifying immune mechanisms protection following i.v. BCG will facilitate development of more effective vaccines against TB. Here, we depleted lymphocyte subsets prior to and during Mtb challenge in i.v. BCG-vaccinated macaques to identify those necessary for protection. Depletion of adaptive CD4 T cells, but not adaptive CD8αβ T cells, resulted in loss of protection with increased Mtb burdens and dissemination, indicating that CD4 T cells are critical to i.v. BCG-mediated protection. Depletion of unconventional CD8α-expressing lymphocytes (NK cells, innate T cells, and CD4+CD8α+ double-positive T cells) abrogated protection in most i.v. BCG-immunized macaques, supporting further investigation into which of these cell subsets contribute to protection after vaccination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.